SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI).
Paolisso P, Belmonte M, Gallinoro E, Scarsini R, Bergamaschi L, Portolan L, Armillotta M, Esposito G, Moscarella E, Benfari G, Montalto C, Shumkova M, de Oliveira EK, Angeli F, Orzalkiewicz M, Fabroni M, Baydaroglu N, Munafò AR, D'Atri DO, Casenghi M, Scisciola L, Barbieri M, Marfella R, Gragnano F, Conte E, Pellegrini D, Ielasi A, Andreini D, Penicka M, Oreglia JA, Calabrò P, Bartorelli A, Pizzi C, Palmerini T, Vanderheyden M, Saia F, Ribichini F, Barbato E.
Paolisso P, et al. Among authors: vanderheyden m.
Cardiovasc Diabetol. 2024 Nov 21;23(1):420. doi: 10.1186/s12933-024-02504-8.
Cardiovasc Diabetol. 2024.
PMID: 39574095
Free PMC article.